<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691236</url>
  </required_header>
  <id_info>
    <org_study_id>382</org_study_id>
    <nct_id>NCT00691236</nct_id>
  </id_info>
  <brief_title>Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma</brief_title>
  <acronym>ZOL</acronym>
  <official_title>Evaluation of Zoledronic Acid as a Single Agent and as an Adjuvant to Chemotherapy in the Management of High Grade Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be a pilot study to find out if zoledronic acid improves the response to
      chemotherapy in high grade osteosarcoma. In arm A of the study, 40 adult patients will be
      randomised into two groups. One group will get standard chemotherapy and the other group will
      get Zoledronic acid in addition to chemotherapy. The investigators will assess the
      histological necrosis as well as disease status for up to 2 years.

      In Arm B, adult patients with relapsed disease or advanced disease who are unable to take any
      other therapy and are given only symptomatic care will be given 6 doses of zoledronic acid
      and followed up for disease status. This will be to determine the role of zoledronic acid as
      a single agent.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>histological response disease free interval</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zoledronic acid prior to standard chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zoledronic acid alone 4mg IV 3 weekly for 6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>4mg IV 3 weekly for 6 doses</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Zolendron,</other_name>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy</intervention_name>
    <description>Adriamycin + Cisplatinum and Ifosfamide</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Holoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (between the ages of 18 to 65 years) with a recently diagnosed high
             grade osteosarcoma of the extremity

          2. Non Metastatic at presentation. The metastases are ruled out by a CT scan of the chest
             and a PET scan.

          3. Patients are willing and able to afford the standard chemotherapy.

        Exclusion Criteria:

          1. Non-extremity sarcomas. (pelvis and spine)

          2. Age less than 18 years or greater than 65 years

          3. Metastatic at presentation

          4. Pregnant or lactating women

          5. Renal dysfunction in the form of elevated serum creatinine

          6. Dental treatment anticipated after evaluation.

          7. Patients who have received or are likely to receive steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Agarwal, M.S(Orth)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tata Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manish G Agarwal, M.S(Orth)</last_name>
    <phone>91-22-2444-7189</phone>
    <email>mgagarwal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ajay Puri, M.S(Orth)</last_name>
    <phone>91-22-2417-7183</phone>
    <email>docpuri@vsnl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manish G Agarwal, M.S(Orth)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Manish Agarwal</name_title>
    <organization>Tata Memorial Hospital</organization>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>bisphosphonates</keyword>
  <keyword>adjuvant to chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

